Invention Grant
- Patent Title: Humanized anti-EMAP II antibody and use thereof
- Patent Title (中): 人源化抗EMAP II抗体及其用途
-
Application No.: US14113209Application Date: 2011-07-14
-
Publication No.: US09382316B2Publication Date: 2016-07-05
- Inventor: Kang-Jun Yoon
- Applicant: Kang-Jun Yoon
- Applicant Address: KR Seoul KR Seoul KR Seoul KR Seoul
- Assignee: Cell & Bio Co., Ltd.,L & K Biomed Co., Ltd.,Hee Koung Kim,Sang Gyu Park
- Current Assignee: Cell & Bio Co., Ltd.,L & K Biomed Co., Ltd.,Hee Koung Kim,Sang Gyu Park
- Current Assignee Address: KR Seoul KR Seoul KR Seoul KR Seoul
- Agency: Dentons US LLP
- Agent Stephanie Seidman
- Priority: KR10-2011-0036569 20110420
- International Application: PCT/KR2011/005203 WO 20110714
- International Announcement: WO2012/144692 WO 20121026
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/46 ; C07K16/24 ; C12P21/06 ; C12N1/20 ; C12N15/00 ; C07H21/04 ; C12N15/87 ; A61K39/395 ; C07K16/18
Abstract:
The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II.
Public/Granted literature
- US20140154245A1 HUMANIZED ANTI-EMAP II ANTIBODY AND USE THEREOF Public/Granted day:2014-06-05
Information query
